Symbols / ARWR Stock $76.39 +2.11% Arrowhead Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
ARWR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Christopher R. Anzalone Ph.D.
Exch · Country NMS · United States
Market Cap 10.70B
Enterprise Value 10.25B
Income 202.26M
Sales 1.09B
FCF (ttm) 170.73M
Book/sh 4.14
Cash/sh 6.53
Employees 711
Insider 10d —
IPO Dec 16, 1993
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 47.74
Forward P/E -17.86
PEG —
P/S 9.80
P/B 18.47
P/C —
EV/EBITDA 31.49
EV/Sales 9.40
Quick Ratio 3.26
Current Ratio 3.38
Debt/Eq 124.07
LT Debt/Eq —
EPS (ttm) 1.60
EPS next Y -4.28
EPS Growth —
Revenue Growth 104.61%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-05
ROA 14.35%
ROE 75.50%
ROIC —
Gross Margin 100.00%
Oper. Margin 15.46%
Profit Margin 18.54%
Shs Outstand 140.03M
Shs Float 122.04M
Insider Own 3.78%
Instit Own 79.16%
Short Float 11.98%
Short Ratio 5.82
Short Interest 12.01M
52W High 76.76
vs 52W High -0.48%
52W Low 12.44
vs 52W Low 514.07%
Beta 1.29
Impl. Vol. 66.50%
Rel Volume 0.56
Avg Volume 2.63M
Volume 1.47M
Target (mean) $84.50
Tgt Median $88.00
Tgt Low $35.00
Tgt High $110.00
# Analysts 12
Recom Buy
Prev Close $74.81
Price $76.39
Change 2.11%
About

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$84.50
Mean price target
2. Current target
$76.39
Latest analyst target
3. DCF / Fair value
$21.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$76.39
Low
$35.00
High
$110.00
Mean
$84.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-01 init JP Morgan — → Overweight $88
2026-04-21 up Morgan Stanley Equal-Weight → Overweight $100
2026-03-25 reit HC Wainwright & Co. Buy → Buy $100
2026-02-10 reit HC Wainwright & Co. Buy → Buy $100
2026-01-22 main B. Riley Securities Buy → Buy $101
2026-01-21 main HC Wainwright & Co. Buy → Buy $100
2026-01-13 reit Piper Sandler Overweight → Overweight $110
2026-01-07 main Goldman Sachs Neutral → Neutral $85
2026-01-07 main Morgan Stanley Equal-Weight → Equal-Weight $81
2026-01-07 main Chardan Capital Buy → Buy $80
2025-12-17 main Piper Sandler Overweight → Overweight $100
2025-12-11 main RBC Capital Outperform → Outperform $80
2025-12-09 main B of A Securities Buy → Buy $81
2025-12-02 main HC Wainwright & Co. Buy → Buy $85
2025-12-01 main B of A Securities Buy → Buy $62
2025-12-01 main Chardan Capital Buy → Buy $60
2025-11-26 main Morgan Stanley Equal-Weight → Equal-Weight $48
2025-11-20 main Goldman Sachs Neutral → Neutral $48
2025-11-19 main RBC Capital Outperform → Outperform $52
2025-11-19 main Chardan Capital Buy → Buy $60
News
RSS: Latest ARWR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-23 HAMILTON JAMES C Officer — 10,000 $75.00 $750,000
2026-04-22 APEL DANIEL JOSEPH Chief Financial Officer — 13,095 $70.11 $934,285
2026-03-05 HAMILTON JAMES C Officer — 10,000 $64.19 $641,900
2026-01-06 O'BRIEN PATRICK C Chief Operating Officer — 75,000 $0.00 $0
2026-01-06 O'BRIEN PATRICK C Chief Operating Officer — 2,500 $0.00 $0
2026-01-06 HAMILTON JAMES C Officer — 75,000 $0.00 $0
2026-01-06 APEL DANIEL JOSEPH Chief Financial Officer — 75,000 $0.00 $0
2026-01-05 O'BRIEN PATRICK C Chief Operating Officer — 49,493 $61.12 $3,123,349
2026-01-05 HAMILTON JAMES C Officer — 40,164 $61.24 $2,534,661
2026-01-02 ANZALONE CHRISTOPHER RICHARD Chief Executive Officer — 13,187 $65.88 $871,703
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
829.45
+23258.15%
3.55
-98.52%
240.74
-1.03%
243.23
Operating Revenue
829.45
+23258.15%
3.55
-98.52%
240.74
-1.03%
243.23
Operating Expense
731.10
+20.92%
604.63
+35.65%
445.74
+5.69%
421.74
Research And Development
607.16
+20.02%
505.87
+43.23%
353.19
+18.80%
297.31
Selling General And Administration
121.92
+25.92%
96.82
+6.48%
90.93
-26.92%
124.43
General And Administrative Expense
121.92
+25.92%
96.82
+6.48%
90.93
-26.92%
124.43
Salaries And Wages
62.70
-7.75%
67.97
+1.76%
66.80
-36.48%
105.17
Other Gand A
59.21
+105.25%
28.85
+19.53%
24.14
-80.60%
124.43
Total Expenses
731.10
+20.92%
604.63
+35.65%
445.74
+5.69%
421.74
Operating Income
98.35
+116.36%
-601.08
-193.21%
-205.00
-14.84%
-178.51
Total Operating Income As Reported
98.35
+116.36%
-601.08
-193.21%
-205.00
-14.84%
-178.51
EBITDA
164.82
+129.35%
-561.51
-219.64%
-175.67
-8.25%
-162.29
Normalized EBITDA
164.82
+129.35%
-561.51
-219.64%
-175.67
-8.25%
-162.29
Reconciled Depreciation
23.93
+28.68%
18.59
+48.84%
12.49
+19.88%
10.42
EBIT
140.89
+124.29%
-580.11
-208.30%
-188.16
-8.95%
-172.71
Net Income
-1.63
+99.73%
-599.49
-192.04%
-205.28
-16.59%
-176.06
Pretax Income
51.53
+108.41%
-612.46
-196.60%
-206.49
-19.56%
-172.71
Net Non Operating Interest Income Expense
-52.07
-440.61%
-9.63
-218.20%
-3.03
-160.14%
5.03
Interest Expense Non Operating
89.36
+176.21%
32.35
+76.54%
18.33
0.00
Net Interest Income
-52.07
-440.61%
-9.63
-218.20%
-3.03
-160.14%
5.03
Interest Expense
89.36
+176.21%
32.35
+76.54%
18.33
0.00
Interest Income Non Operating
37.29
+64.12%
22.72
+48.51%
15.30
+203.97%
5.03
Interest Income
37.29
+64.12%
22.72
+48.51%
15.30
+203.97%
5.03
Other Income Expense
5.26
+400.86%
-1.75
-213.65%
1.54
+101.05%
0.77
Other Non Operating Income Expenses
5.26
+400.86%
-1.75
-213.65%
1.54
+101.05%
0.77
Tax Provision
21.42
+874.09%
-2.77
-199.39%
2.78
-26.45%
3.79
Tax Rate For Calcs
0.00
+4100.00%
0.00
-97.62%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
30.11
+104.94%
-609.69
-191.34%
-209.28
-18.57%
-176.49
Net Income From Continuing Operation Net Minority Interest
-1.63
+99.73%
-599.49
-192.04%
-205.28
-16.59%
-176.06
Net Income From Continuing And Discontinued Operation
-1.63
+99.73%
-599.49
-192.04%
-205.28
-16.59%
-176.06
Net Income Continuous Operations
30.11
+104.94%
-609.69
-191.34%
-209.28
-18.57%
-176.49
Minority Interests
-31.75
-411.23%
10.20
+155.00%
4.00
+828.07%
0.43
Normalized Income
-1.63
+99.73%
-599.49
-192.04%
-205.28
-16.59%
-176.06
Net Income Common Stockholders
-1.63
+99.73%
-599.49
-192.04%
-205.28
-16.59%
-176.06
Diluted EPS
-0.01
+99.80%
-5.00
-160.42%
-1.92
-14.97%
-1.67
Basic EPS
-0.01
+99.80%
-5.00
-161.39%
-1.91
-17.36%
-1.63
Basic Average Shares
133.76
+11.67%
119.78
+11.62%
107.31
+1.28%
105.96
Diluted Average Shares
133.76
+11.67%
119.78
+11.62%
107.31
+1.28%
105.96
Diluted NI Availto Com Stockholders
-1.63
+99.73%
-599.49
-192.04%
-205.28
-16.59%
-176.06
Depreciation Amortization Depletion Income Statement
2.03
+4.48%
1.94
+20.04%
1.62
+0.19%
1.61
Depreciation And Amortization In Income Statement
2.03
+4.48%
1.94
+20.04%
1.62
+0.19%
1.61
Total Other Finance Cost
—
—
—
-5.03
Line Item Trend 2025-09-30
Total Assets
1,385.30
Current Assets
950.64
Cash Cash Equivalents And Short Term Investments
919.37
Cash And Cash Equivalents
88.71
Other Short Term Investments
830.66
Receivables
6.82
Accounts Receivable
6.82
Prepaid Assets
10.93
Other Current Assets
13.52
Total Non Current Assets
434.66
Net PPE
426.41
Gross PPE
506.57
Accumulated Depreciation
-80.17
Properties
0.00
Land And Improvements
3.00
Buildings And Improvements
251.32
Machinery Furniture Equipment
6.66
Construction In Progress
15.94
Other Properties
125.24
Leases
104.42
Goodwill And Other Intangible Assets
6.86
Other Intangible Assets
6.86
Investments And Advances
—
Other Non Current Assets
1.39
Total Liabilities Net Minority Interest
881.88
Current Liabilities
195.49
Payables And Accrued Expenses
134.99
Payables
17.67
Accounts Payable
17.67
Current Accrued Expenses
117.31
Current Debt And Capital Lease Obligation
47.29
Current Debt
40.00
Other Current Borrowings
40.00
Current Capital Lease Obligation
7.29
Current Deferred Liabilities
2.40
Current Deferred Revenue
2.40
Other Current Liabilities
10.81
Total Non Current Liabilities Net Minority Interest
686.39
Liabilities Heldfor Sale Non Current
367.40
Long Term Debt And Capital Lease Obligation
319.00
Long Term Debt
214.88
Long Term Capital Lease Obligation
104.11
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Stockholders Equity
466.05
Common Stock Equity
466.05
Capital Stock
0.23
Common Stock
0.23
Share Issued
138.36
Ordinary Shares Number
135.70
Treasury Shares Number
2.66
Additional Paid In Capital
2,139.72
Retained Earnings
-1,627.15
Gains Losses Not Affecting Retained Earnings
6.44
Treasury Stock
53.19
Minority Interest
37.36
Other Equity Adjustments
6.44
Total Equity Gross Minority Interest
503.42
Total Capitalization
680.93
Working Capital
755.15
Invested Capital
720.93
Total Debt
366.28
Net Debt
166.18
Capital Lease Obligations
111.40
Net Tangible Assets
459.19
Tangible Book Value
459.19
Held To Maturity Securities
—
Investmentin Financial Assets
—
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
179.55
+138.79%
-462.85
-200.77%
-153.89
-13.05%
-136.13
Cash Flow From Continuing Operating Activities
179.55
+138.79%
-462.85
-200.77%
-153.89
-13.05%
-136.13
Net Income From Continuing Operations
30.11
+104.94%
-609.69
-191.34%
-209.28
-18.57%
-176.49
Depreciation Amortization Depletion
23.93
+28.68%
18.59
+48.84%
12.49
+19.88%
10.42
Depreciation And Amortization
23.93
+28.68%
18.59
+48.84%
12.49
+19.88%
10.42
Other Non Cash Items
89.36
+176.21%
32.35
+76.54%
18.33
+529.76%
2.91
Stock Based Compensation
63.37
-14.33%
73.97
-5.33%
78.13
-35.37%
120.89
Operating Gains Losses
-3.19
-4091.25%
0.08
—
4.43
Gain Loss On Investment Securities
-3.19
-4091.25%
0.08
—
4.43
Change In Working Capital
-18.23
-172.68%
25.09
+148.68%
-51.55
+47.56%
-98.29
Change In Receivables
-56.97
0.00
-100.00%
1.41
-84.06%
8.85
Changes In Account Receivables
-56.97
0.00
-100.00%
1.41
-84.06%
8.85
Change In Prepaid Assets
-9.94
-497.30%
-1.66
-114.34%
11.60
+160.15%
-19.29
Change In Payables And Accrued Expense
47.78
+79.76%
26.58
+47.40%
18.03
+61.57%
11.16
Change In Accrued Expense
41.50
+29.21%
32.12
+314.61%
-14.96
-184.31%
17.75
Change In Payable
6.29
+213.55%
-5.54
-116.78%
33.00
+600.80%
-6.59
Change In Account Payable
6.29
+213.55%
-5.54
-116.78%
33.00
+600.80%
-6.59
Change In Other Working Capital
5.49
+365.88%
-2.07
+98.40%
-129.18
-30.48%
-99.01
Change In Other Current Liabilities
-4.61
-305.58%
2.24
-95.19%
46.59
—
Investing Cash Flow
-129.29
+69.22%
-420.07
-336.87%
-96.16
-1675.06%
-5.42
Cash Flow From Continuing Investing Activities
-129.29
+69.22%
-420.07
-336.87%
-96.16
-1675.06%
-5.42
Net PPE Purchase And Sale
-22.67
+83.98%
-141.47
+19.96%
-176.74
-234.88%
-52.78
Purchase Of PPE
-22.67
+83.98%
-141.47
+19.96%
-176.74
-234.88%
-52.78
Capital Expenditure
-22.67
+83.98%
-141.47
+19.96%
-176.74
-234.88%
-52.78
Net Investment Purchase And Sale
-106.63
+61.73%
-278.60
-445.74%
80.58
+70.15%
47.36
Purchase Of Investment
-796.26
-10.45%
-720.95
-192.90%
-246.14
-10.18%
-223.39
Sale Of Investment
689.63
+55.90%
442.34
+35.39%
326.72
+20.67%
270.75
Financing Cash Flow
74.01
-91.50%
870.52
+244.01%
253.05
+288.20%
65.19
Cash Flow From Continuing Financing Activities
74.01
-91.50%
870.52
+244.01%
253.05
+288.20%
65.19
Net Issuance Payments Of Debt
-191.37
-148.82%
392.00
0.00
0.00
Issuance Of Debt
10.26
-97.38%
392.00
0.00
0.00
Repayment Of Debt
-201.62
0.00
0.00
—
Long Term Debt Issuance
0.00
-100.00%
392.00
0.00
0.00
Long Term Debt Payments
-201.62
0.00
0.00
—
Net Long Term Debt Issuance
-201.62
-151.43%
392.00
0.00
0.00
Short Term Debt Issuance
10.26
0.00
0.00
—
Net Short Term Debt Issuance
10.26
0.00
0.00
—
Net Common Stock Issuance
241.39
-43.77%
429.26
0.00
0.00
Proceeds From Stock Option Exercised
28.98
+1113.19%
2.39
-21.75%
3.05
-41.13%
5.19
Net Other Financing Charges
-5.00
-110.67%
46.87
-81.25%
250.00
+316.67%
60.00
Changes In Cash
124.26
+1101.89%
-12.40
-512.33%
3.01
+103.94%
-76.36
Effect Of Exchange Rate Changes
-0.40
-109.55%
4.20
+3540.16%
-0.12
-82.09%
-0.07
Beginning Cash Position
102.69
-7.40%
110.89
+2.67%
108.00
-41.44%
184.43
End Cash Position
226.55
+120.62%
102.69
-7.40%
110.89
+2.67%
108.00
Free Cash Flow
156.89
+125.96%
-604.32
-82.78%
-330.63
-75.02%
-188.91
Interest Paid Supplemental Data
0.02
0.00
0.00
0.00
Income Tax Paid Supplemental Data
—
3.74
0.00
-100.00%
0.00
Amortization Of Securities
-5.79
-78.45%
-3.24
-60.83%
-2.02
-169.31%
2.91
Common Stock Issuance
241.39
-43.77%
429.26
0.00
0.00
Issuance Of Capital Stock
241.39
-43.77%
429.26
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category